[HTML][HTML] Harnessing minimal residual disease as a predictor for colorectal cancer: Promising horizons amidst challenges
X Wen, D Coradduzza, J Shen, AM Scanu, MR Muroni… - Medicina, 2023 - mdpi.com
Minimal Residual Disease (MRD) detection has emerged as an independent factor in
clinical and pathological cancer assessment offering a highly effective method for predicting …
clinical and pathological cancer assessment offering a highly effective method for predicting …
[HTML][HTML] minimal residual disease in colorectal cancer: are we finding the needle in a Haystack?
AA Jácome, B Johnson - Cells, 2023 - mdpi.com
Despite significant advances in the surgical and systemic therapy of colorectal cancer (CRC)
in recent decades, recurrence rates remain high. Apart from microsatellite instability status …
in recent decades, recurrence rates remain high. Apart from microsatellite instability status …
[HTML][HTML] Bioinformatics analysis-based screening of circRNA gene with mainstream expression trend in colorectal cancer and construction of a coexpression …
L Xu, H Zhang, Y Shao, Z Fu - Plos one, 2023 - journals.plos.org
Objective Since circRNA can be utilized as a potential diagnostic marker for cancer, to
explore the regulatory mechanism of colorectal cancer (CRC) using bioinformatics, the …
explore the regulatory mechanism of colorectal cancer (CRC) using bioinformatics, the …
Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration Resistant Prostate Cancer
CJ Sweeney, R Petry, C Xu, M Childress… - Clinical Cancer …, 2024 - aacrjournals.org
Purpose: Enzalutamide after abiraterone progression is commonly used in metastatic
castration resistant prostate cancer (mCRPC) despite a low rate of clinical benefit. Analyzing …
castration resistant prostate cancer (mCRPC) despite a low rate of clinical benefit. Analyzing …
[HTML][HTML] Analytical validation of a novel comprehensive genomic profiling informed circulating tumor DNA monitoring assay for solid tumors
DR Zollinger, E Rivers, A Fine, Y Huang, J Son… - Plos one, 2024 - journals.plos.org
Emerging technologies focused on the detection and quantification of circulating tumor DNA
(ctDNA) in blood show extensive potential for managing patient treatment decisions …
(ctDNA) in blood show extensive potential for managing patient treatment decisions …
Not all TMB assays are the same: clinical validity of robust algorithmic germline filtering
Not all TMB assays are the same: Clinical validity of robust algorithmic germline filtering Not
all TMB assays are the same: Clinical validity of robust algorithmic germline filtering Cancer …
all TMB assays are the same: Clinical validity of robust algorithmic germline filtering Cancer …
[HTML][HTML] The ideal reporting of RAS testing in colorectal adenocarcinoma: a pathologists' perspective
U Malapelle, V Angerilli, F Pepe, G Fontanini… - Pathologica, 2023 - ncbi.nlm.nih.gov
RAS gene mutational status represents an imperative predictive biomarker to be tested in
the clinical management of metastatic colorectal adenocarcinoma. Even if it is one of the …
the clinical management of metastatic colorectal adenocarcinoma. Even if it is one of the …
[HTML][HTML] Racial disparities in metastatic colorectal cancer outcomes revealed by tumor microbiome and transcriptome analysis with bevacizumab treatment
L Feng, R Wang, Q Zhao, J Wang, G Luo… - Frontiers in …, 2024 - frontiersin.org
Background: Metastatic colorectal cancer (mCRC) is a heterogeneous disease, often
associated with poor outcomes and resistance to therapies. The racial variations in the …
associated with poor outcomes and resistance to therapies. The racial variations in the …
[HTML][HTML] Histology independent drug development–Is this the future for cancer drugs?
L Billingham, L Brown, T Framke, A Greystoke… - Cancer Treatment …, 2023 - Elsevier
Abstract The Cancer Drug Development Forum (CDDF)'s 'Histology independent drug
development–is this the future for cancer drugs?'workshop was set up to explore the current …
development–is this the future for cancer drugs?'workshop was set up to explore the current …
ctDNA-guided adjuvant treatment after radical-intent treatment of metastatic spread from colorectal cancer—the first interim results from the OPTIMISE study
LB Callesen, TF Hansen, RF Andersen… - Acta …, 2023 - Taylor & Francis
Background Patients with detectable ctDNA after radical-intent treatment of metastatic
spread from colorectal cancer (mCRC) have a very high risk of recurrence, which may be …
spread from colorectal cancer (mCRC) have a very high risk of recurrence, which may be …